Cardiotoxicity: Causes, Symptoms, and Treatment

Cardiotoxicity refers to damage or dysfunction of the heart caused by chemical substances, and it spans a wide range of problems from temporary blood pressure spikes to irreversible heart failure. The term comes up most often in cancer care, where powerful drugs can harm the heart as a side effect, but recreational drugs and radiation therapy also carry well-documented cardiac risks. What makes cardiotoxicity tricky is that it does not always announce itself with obvious symptoms, and it can surface months or even years after the exposure that caused it.

What Causes Cardiotoxicity

The list of agents that can injure the heart is longer than most people expect. In oncology alone, several entire classes of drugs carry cardiac risk, each through a different mechanism. Outside of cancer treatment, illicit stimulants and chest-directed radiation round out the most common culprits.

Anthracyclines

Drugs like doxorubicin and epirubicin remain among the most effective chemotherapy agents, but they are also among the most consistently cardiotoxic. For decades, researchers thought the damage was straightforward: anthracyclines disrupt iron metabolism in heart cells and unleash a flood of harmful free radicals. That picture has grown more complicated. Experimental data now point to additional mechanisms including inhibition of a specific enzyme in heart muscle cells, inflammatory signaling, and disrupted cellular recycling processes.¹ The damage from anthracyclines is classified as “type I” cardiac dysfunction, meaning it tends to be cumulative, dose-dependent, and at least partially irreversible. Higher lifetime doses carry steeper risk, and the heart injury can persist even after the drug is stopped.²

Trastuzumab and Other Targeted Therapies

Trastuzumab (Herceptin), a cornerstone of HER2-positive breast cancer treatment, damages the heart through a fundamentally different pathway than anthracyclines. It was initially considered less worrisome because its cardiac effects appeared to be reversible once the drug was stopped and did not show the same structural damage to heart muscle cells seen with anthracyclines.³ That said, more recent evidence suggests trastuzumab’s cardiac effects deserve greater clinical concern than originally thought.² The risk is especially pronounced when trastuzumab is given after or alongside anthracyclines, stacking one form of cardiac stress on top of another.

Tyrosine Kinase Inhibitors

Tyrosine kinase inhibitors (TKIs) are a broad drug family used across many cancer types, and their cardiac side effects vary considerably depending on the specific drug. Those that block vascular endothelial growth factor, used heavily in kidney and liver cancers, are strongly linked to high blood pressure and arterial blockages.⁴ Sunitinib, one of the most studied drugs in this category, causes hypertension and cardiac toxicity through mechanisms that remain incompletely understood.⁵ A different branch of TKIs used in blood cancers, Bruton tyrosine kinase inhibitors, has been tied to irregular heart rhythms and hypertension. Interestingly, not all TKIs are equal offenders: imatinib, one of the earliest in the class, may actually be protective to the heart.⁴

Proteasome Inhibitors

These drugs anchor the treatment of multiple myeloma and related blood disorders. Carfilzomib, an irreversible proteasome inhibitor given intravenously, has the most severe cardiovascular profile in the class, producing heart failure, hypertension, abnormal heart rhythms, and coronary events.⁶ In a large analysis of reported adverse events, heart failure was the most common cardiac problem linked to carfilzomib, accounting for over a thousand events, roughly two-thirds of which were classified as serious.⁷ Older and reversible proteasome inhibitors like bortezomib carry lower cardiac risk by comparison.⁸

Immune Checkpoint Inhibitors

Checkpoint inhibitors unleash the immune system against cancer, but that same unleashed immune response can attack the heart. The resulting myocarditis (inflammation of the heart muscle) is uncommon but dangerous when it occurs. Symptoms are highly variable: in a review of reported cases, about half of patients presented with cardiac symptoms like chest pain and shortness of breath, roughly a third had neuromuscular symptoms such as muscle weakness or drooping eyelids, and about one in ten had no symptoms at all, with the problem caught only on lab tests or imaging.⁹

5-Fluorouracil

This older chemotherapy drug, still widely used in gastrointestinal and other cancers, causes cardiac trouble primarily through coronary vasospasm, a sudden constriction of the blood vessels feeding the heart. One study found that half of patients developed spasm in a monitored artery after receiving 5-FU, while patients on non-5-FU regimens did not. Additional mechanisms include formation of small blood clots and overstimulation of the nervous system that drives up heart rate.¹⁰ Symptoms tend to appear quickly, often within the first week of treatment.

Radiation Therapy

Radiation directed at or near the chest, particularly for breast cancer, Hodgkin lymphoma, and lung cancer, can damage every component of the heart. It causes scarring (fibrosis) that significantly raises the risk of coronary artery disease, heart muscle damage, valve disease, rhythm problems, and inflammation of the sac around the heart.¹¹ These problems often take years or decades to show up, making radiation-induced heart disease one of the most underrecognized forms of cardiotoxicity.¹²

Illicit Stimulants

Cocaine and methamphetamine are highly cardiotoxic outside any medical context. They ramp up the heart’s demand for oxygen through stimulation of the sympathetic nervous system while simultaneously constricting blood vessels and reducing oxygen supply. That mismatch leads to ischemia, heart attacks, and rhythm disturbances.¹³ Both drugs also alter the electrical properties of heart cells through multiple pathways, promoting both dangerously fast and dangerously slow heart rhythms.¹⁴

Symptoms and Timing

Cardiotoxicity does not have a single symptom fingerprint. What you feel depends on the type of cardiac damage, and sometimes you feel nothing at all until the problem is advanced. In patients undergoing cancer treatment, the five most commonly reported symptoms are shortness of breath, chest pain, swelling in the legs or ankles, fatigue, and palpitations.¹⁵ Less common but documented presentations include abnormal EKG findings, blood pressure changes, inflammation of the heart’s lining, and in severe cases, cardiac tamponade (dangerous fluid buildup around the heart) or outright heart failure.¹⁶

Timing varies dramatically by the causative agent. In breast cancer patients, anthracycline-based regimens typically triggered first symptoms within a few days to about two months. Trastuzumab-related symptoms appeared much later, anywhere from two months to nearly a year after starting treatment. Capecitabine, a relative of 5-FU, caused symptoms within the first week.¹⁵ Some cardiac effects, particularly those from anthracyclines and radiation, may not become apparent until months or years after treatment ends.¹⁶

How Cardiotoxicity Is Detected

Because symptoms are often absent or vague, detection increasingly relies on objective measurements: blood tests, imaging, and emerging computational tools.

Blood Biomarkers

Two families of cardiac blood tests have shown the most promise. Troponin, the same protein measured after a suspected heart attack, can rise when chemotherapy damages heart muscle cells. BNP and its related form NT-proBNP, hormones released when the heart is under strain, have been associated with increased mortality in cancer patients and can predict the onset of heart failure before symptoms develop.¹⁷ In one breast cancer trial, small but measurable rises in NT-proBNP appeared early in patients who went on to develop cardiac problems, while troponin rose in both affected and unaffected patients, making it less specific in that particular setting.¹⁸ The practical upside is that a simple blood draw done at intervals during treatment can flag trouble before the heart’s pumping function visibly drops.¹⁹ Troponin also appears highly sensitive for detecting checkpoint-inhibitor-related myocarditis specifically.¹⁷

Imaging With Strain Measurements

The traditional imaging yardstick for cardiotoxicity is the left ventricular ejection fraction (LVEF), essentially how much blood the heart ejects with each beat. But LVEF tends to drop only after significant damage has already occurred. A more sensitive measure is global longitudinal strain (GLS), which tracks how well the heart muscle deforms during contraction. A systematic review found that changes in strain consistently precede changes in ejection fraction, and that a roughly 10 to 15 percent early reduction in GLS during therapy is the most useful warning sign.²⁰ In a Dutch study of breast cancer patients, the decline in GLS preceded the drop in LVEF by about 30 days on average, giving clinicians a meaningful head start.²¹

Artificial Intelligence and Continuous Monitoring

A newer and still evolving frontier is the use of artificial intelligence applied to standard EKG recordings. In one study, an AI model trained on baseline EKGs before chemotherapy stratified patients into risk groups: those flagged as high risk developed cardiac dysfunction at roughly three times the rate of low-risk patients, even after accounting for traditional risk factors like age, existing heart disease, and cancer type.²² Similar AI approaches applied to EKG images have shown promise in stratifying risk specifically among patients receiving anthracyclines or trastuzumab for breast cancer and lymphoma.²³ Beyond prediction, wearable EKG patches and biosensors are being explored to allow continuous cardiac surveillance during chemotherapy, rather than relying solely on periodic clinic visits.²⁴

Prevention Strategies

Once you know a treatment carries cardiac risk, the logical question is whether anything can be done to protect the heart without weakening the cancer treatment. Several approaches have real evidence behind them.

Dexrazoxane

Dexrazoxane is the only drug specifically approved as a cardioprotective agent during anthracycline chemotherapy. In a large randomized trial of patients with advanced breast cancer, those who received dexrazoxane alongside their anthracycline experienced far fewer cardiac events: about 13 percent had a cardiac event compared with 39 percent among those who received the anthracycline alone. The rate of congestive heart failure dropped from roughly 11 percent to 1 percent, and tumor response was not affected.²⁵ Long-term follow-up in children treated for leukemia confirmed that dexrazoxane provided lasting heart protection without compromising cancer outcomes, with girls benefiting more than boys.²⁶

Heart Failure Medications Used Preventively

Standard heart failure drugs, particularly ACE inhibitors, angiotensin receptor blockers (ARBs), and beta-blockers, have been studied as preventive agents during cancer treatment. A meta-analysis of breast cancer patients found that all three drug classes significantly preserved heart pumping function compared with placebo. The combination of an ACE inhibitor or ARB with a beta-blocker also showed a clear benefit.²⁷ These medications are not routinely given to every patient on chemotherapy, but they are increasingly used in patients identified as being at higher cardiac risk before or during treatment.

Exercise

Physical activity during and after cancer treatment is gaining recognition as a legitimate cardioprotective intervention, not just a general wellness recommendation. A randomized trial testing a structured exercise-based cardio-oncology rehabilitation program during breast cancer chemotherapy found that the decline in heart pumping function was significantly smaller in the exercise group. Participants in the program also had meaningful reductions in body mass index, particularly those who were obese at baseline.²⁸ Broader reviews of the literature have found beneficial effects of exercise in both early and late phases of cancer treatment as well as during rehabilitation afterward.²⁹

Treatment When Cardiotoxicity Develops

When prevention fails or cardiotoxicity is discovered after the fact, treatment depends heavily on the specific type of heart damage and the drug that caused it.

For anthracycline-induced heart failure, the approach is largely the same as for heart failure from any cause: ACE inhibitors or ARBs, beta-blockers, diuretics when fluid overload is present, and in severe cases, more advanced therapies. The complicating factor is that anthracycline damage involves structural changes to heart cells, so recovery may be incomplete even with optimal medical therapy.

Trastuzumab-related cardiac dysfunction is generally more forgiving. Patients who develop heart problems while on trastuzumab typically improve once the drug is stopped, and the structural damage seen with anthracyclines is largely absent.³ This is clinically important because it allows for treatment interruption and potential rechallenge: patients may be able to resume trastuzumab after cardiac function recovers, under close monitoring.

Checkpoint-inhibitor myocarditis requires an entirely different playbook. High-dose corticosteroids are the first-line treatment, aimed at dampening the overactive immune response attacking the heart. When patients do not respond to steroids, options become limited but may include drugs like infliximab, an immune-suppressing antibody more commonly used in autoimmune conditions.³⁰ This is still an area where evidence is thin and treatment is guided more by clinical experience than large trials.

The Cardio-Oncology Model

One of the more meaningful developments in managing cardiotoxicity has been the emergence of dedicated cardio-oncology programs where cardiologists and oncologists work side by side. The core idea is simple but powerful: instead of a cancer doctor and a heart doctor operating in separate silos, a joint team coordinates care from the start. These multidisciplinary programs have been linked to better clinical outcomes, improved recovery of heart function, fewer adverse events, and critically, a greater ability to keep patients on their cancer therapies rather than abandoning effective treatment out of cardiac fear.³¹ Early access to a cardio-oncology clinic also helps patients address broader cardiovascular risk factors like high cholesterol or diabetes that can compound drug-related cardiac damage.³² Not every hospital has such a program yet, but the model is expanding.

Childhood Cancer Survivors and Long-Term Risk

Children who survive cancer face a particularly unfair trade: decades of life gained, but often with elevated cardiac risk that persists long after treatment ends. A systematic review of long-term outcomes confirmed that cardiovascular and metabolic disease risks are significantly higher in childhood cancer survivors, shaped by the type of cancer, the therapy used, and factors like age, sex, and ethnicity.³³ Anthracyclines and chest radiation are the primary drivers. Higher cumulative anthracycline doses clearly increase the risk of heart failure, though even lower doses have been linked to cardiac abnormalities in susceptible individuals. Radiation to the heart area, especially when combined with anthracyclines, compounds the danger further.³⁴

The insidious part is that many survivors walk around with significant underlying cardiac problems without symptoms, which means damage can progress silently for years. The American Heart Association has emphasized the need for systematic lifelong cardiovascular monitoring and the importance of smoothly transitioning survivors from pediatric to adult cardiac care, a handoff that does not always happen reliably.³⁵ Practical surveillance for these patients includes regular echocardiograms, blood biomarker testing, and attention to lifestyle factors like exercise and diet.³³

Why Some People Are More Vulnerable Than Others

One of the persistent puzzles in cardiotoxicity is individual susceptibility. Two patients can receive the same drug at the same dose, and one develops heart failure while the other sails through. Traditional risk factors explain part of the difference: pre-existing heart disease, diabetes, obesity, older age, and prior radiation to the chest all elevate risk. But they do not explain all of it.

Genetic variation is increasingly suspected as a major contributor. Researchers have pursued both targeted gene studies and broader genome-wide scans to find genetic markers that predict who will develop cardiac damage from chemotherapy, but the results have been elusive. The challenge is that cardiotoxicity likely involves many genes with small individual effects, making it hard to find clear-cut risk markers.³⁶ Newer laboratory tools using heart cells grown from a patient’s own stem cells offer a promising way to test drug sensitivity before treatment begins, though this approach is still largely experimental. The hope is that future patients could be screened genetically or through laboratory testing before chemotherapy, allowing doctors to tailor regimens to individual cardiac vulnerability rather than relying on population-level averages.

1
PubMed. Cardiac Damage in Anthracyclines Therapy: Focus on Oxidative Stress and Inflammation
2
PubMed Central. Mechanisms of trastuzumab induced cardiotoxicity – is exercise a potential treatment?
3
PubMed. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment
4
PubMed Central. Cardiovascular Toxicities Associated with Tyrosine Kinase Inhibitors
5
PubMed. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels
6
Frontiers in Pharmacology. Carfilzomib in multiple myeloma: unraveling cardiac toxicities – from mechanisms to diagnosis and management
7
PubMed Central. Carfilzomib-induced Cardiotoxicity: An Analysis of the FDA Adverse Event Reporting System (FAERS)
8
PubMed Central. Cardiovascular Toxicity of Proteasome Inhibitors: Underlying Mechanisms and Management Strategies
9
PubMed Central. Immune Checkpoint Inhibitors-Related Myocarditis: A Review of Reported Clinical Cases
10
American Journal of Case Reports. 5-Fluorouracil Rechallenge After Cardiotoxicity
11
PubMed Central. Radiation-Induced Cardiovascular Disease: Review of an Underrecognized Pathology
12
PubMed Central. Radiation-induced heart disease: a review of classification, mechanism and prevention
13
PubMed Central. Stimulant-Involved Cardiovascular Disease Mortality and Life Years Lost, 2014 to 2023
14
PubMed Central. Stimulant Drugs of Abuse and Cardiac Arrhythmias
15
PubMed Central. Chemotherapy-related cardiotoxicity and its symptoms in patients with breast cancer: a scoping review
16
PubMed. Cardiotoxicity of cancer chemotherapy: implications for children
17
PubMed Central. Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity
18
PubMed Central. Cardiotoxicity and Cardiovascular Biomarkers in Patients With Breast Cancer: Data From the GeparOcto-GBG 84 Trial
19
Journal of Cardiac Failure. The Utility of Point-of-Care Biomarkers to Detect Cardiotoxicity During Anthracycline Chemotherapy: A Feasibility Study
20
PubMed. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review
21
PubMed Central. Global longitudinal strain: an early marker for cardiotoxicity in patients treated for breast cancer
22
Nature Communications. Artificial intelligence-enabled prediction of chemotherapy-induced cardiotoxicity from baseline electrocardiograms
23
PubMed Central. Artificial Intelligence-Enhanced Risk Stratification of Cancer Therapeutics-Related Cardiac Dysfunction Using Electrocardiographic Images
24
PubMed Central. AI and Smart Devices in Cardio-Oncology: Advancements in Cardiotoxicity Prediction and Cardiovascular Monitoring
25
Annals of Oncology. Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane®) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy
26
The Lancet Oncology. Long-term effects of dexrazoxane in patients given anthracyclines for childhood acute lymphoblastic leukaemia: a follow-up of a multicentre, randomised, open-label trial
27
PubMed Central. ACEI/ARB and beta-blocker therapies for preventing cardiotoxicity of antineoplastic agents in breast cancer: a systematic review and meta-analysis
28
Progress in Cardiovascular Diseases. Exercise-based cardio-oncology rehabilitation for cardiotoxicity prevention during breast cancer chemotherapy: The ONCORE randomized controlled trial
29
PubMed Central. Exercise training in cancer related cardiomyopathy
30
PubMed Central. Treatment of corticosteroid refractory immune checkpoint inhibitor myocarditis with Infliximab: a case series
31
ESC Heart Failure. The Impact of a Multidisciplinary Cardio-Oncology Programme on Cardiovascular Outcomes in Taiwan
32
PubMed Central. Early access to a cardio-oncology clinic in an Australian context: a qualitative exploration of patient experiences
33
PubMed Central. Long-Term Cardiovascular Outcomes in Childhood Cancer Survivors: A Systematic Review
34
PubMed Central. Heart failure in long-term survivors of childhood cancer – a systematic review and meta-analysis of population-based studies
35
PubMed Central. Cardiovascular Toxicity in Patients Treated for Childhood Cancer: A Scientific Statement From the American Heart Association
36
Pharmacology & Therapeutics. Validating the pharmacogenomics of chemotherapy-induced cardiotoxicity: What is missing?